Cancer Organoid

Non-Small Cell Lung Cancer Organoid

These organoids are useful for studying genetic mutations in lung cancer and testing the efficacy of various chemotherapy treatments.
They exhibit protein expression patterns of CK5/6, CK7, P40, and TTF-1, allowing for the distinction between different subtypes of lung cancer.
hLC organoids replicate the characteristics of lung cancer tissue.


Price	1784€+ Login to see price
Organism	Human
Product Type	Organoid
Tissue	Lung alveoli, Bronchi
Disease	Non-Small Cell Lung Cancer

Applications

Oncology

Small Molecule

Antibody

Cancer Vaccine

mRNA

Immune Cell

TME-CAF

Immuno Oncology

Macrophage

Regulatory T Cell

Tumor-Infiltrating Lymphocyte

Cytotoxic T Cell

Description

Lung cancer organoid

Our lung cancer organoids accurately replicate patient tumors by expressing key markers TTF-1, CK7, p40 and CK5/6, underscoring their fidelity for cancer research and personalized treatment development.

This molecular mimicry enables a profound understanding of lung cancer pathology and offers a promising avenue for therapeutic innovations.

Lung cancer organoid

		H&E	TTF-1	CK7	p40 (ΔNp63)	CK5/6
Cancer tissue	Adenocarcinoma
Cancer tissue	Adenosquamous
Cancer organoid	Adenocarcinoma
Cancer organoid	Adenosquamous

Genetic mutation

Unlock the essence of precision in cancer treatment with our lung cancer organoids, mirroring the genetic markers of lung cancer.  Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing Dive into a new era of oncology, where your individuality guides our innovation.

Top mutated genes

Lung cancer mutation PPI Network

Genetic analysis in lung cancer organoids

Utilizing a database of protein interactions and mutations, we statistically analyze genetic correlations to identify significant relationships in lung cancer organoids.

Drug response

Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses. Transform the standard with us—where your medication’s potential is as unique as you are.


Cisplatin
	Ctr	1μM	3μM	12μM	50μM
Carboplatin
	Ctr	1μM	3μM	12μM	50μM
Gemcitabine
	Ctr	0.03μM	0.125μM	0.5μM	2μM
Paclitaxel
	Ctr	0.25μM	0.5μM	1μM	20μM

Drug responses of patient-derived lung cancer organoids. Dose-response curves generated from patient-derived lung cancer organoid lines treated with carboplatin, cisplatin, gemcitabine and paclitaxel.
These figures demonstrate the percent of cell viability measured by celltiter-Glo assay.

Non-Small Cell Lung Cancer Organoid

Non-Small Cell Lung Cancer Organoid